Keyphrases
Fertility Preservation
97%
Chemotherapy
60%
Oocyte Cryopreservation
57%
Ovarian Tissue
56%
Transplantation
42%
Cancer Patients
36%
Chemotherapy-induced
35%
Ovarian Tissue Transplantation
33%
Infertility
31%
In Vitro Fertilization
31%
Primordial Follicle
30%
Cyclophosphamide
30%
Follicle Loss
27%
Ovarian Damage
27%
Follicle Activation
27%
Ovarian Reserve
26%
Breast Cancer
23%
Cryopreserved Ovarian Tissue
23%
Cancer Treatment
22%
Live Birth
17%
Controlled Ovarian Stimulation
17%
Polycystic Ovary Syndrome
17%
Preserve Fertility
17%
In Cancer
16%
Oocyte Retrieval
15%
Follicle
15%
Radiotherapy
15%
Autotransplantation
14%
Cryopreserved
13%
Preservation Methods
13%
Intracytoplasmic Sperm Injection
13%
Ovarian Failure
13%
Reproductive Outcome
13%
Hematological Malignancies
13%
Reproductive Performance
13%
Oocyte Collection
12%
Bi-national
12%
Cryopreservation
12%
BRCA mutation Carriers
12%
Breast Cancer Patients
12%
Success Rate
12%
Elective Egg Freezing
11%
Tissue Harvest
11%
Young Cancer Patients
11%
Gonadotropin-releasing Hormone
11%
Ovulation Induction
11%
Young Female
11%
Assisted Reproductive Technology
11%
Leukemia
10%
Ovarian Stimulation
10%
Medicine and Dentistry
Fertility Preservation
100%
Malignant Neoplasm
80%
Follicle
55%
Ovarian Tissue Cryopreservation
44%
Breast Cancer
42%
In Vitro Fertilisation
38%
Primordial Follicle
35%
Oocyte
35%
Cryopreservation
28%
Ovarian Reserve
27%
Cyclophosphamide
26%
Reproductive Medicine
22%
Tissue Transplantation
22%
Diseases
20%
Ovary Insufficiency
20%
Radiation Therapy
19%
Cancer
18%
Autotransplantation
17%
Cancer Treatment
16%
Leukemia
16%
Assisted Reproductive Technology
16%
Surgical Technique
15%
Congenital Malformation
14%
Oocyte Retrieval
14%
Hematologic Malignancy
13%
Intracytoplasmic Sperm Injection
13%
Primary Ovarian Insufficiency
13%
Ovary Function
13%
Fertilization
12%
Follitropin
12%
Polycystic Ovary Syndrome
11%
Oncology
11%
Ovulation Induction
10%
Cancer Cell
10%
Neoplasm
10%
Cancer Therapy
10%
Drug Megadose
10%
BRCA Mutation
10%
Maturation
10%
Minimal Residual Disease
10%
Programmed Cell Death
9%
Reproductive System
9%
BRCA1
9%
Pregnancy Rate
9%
Replantation
9%
Muellerian Inhibiting Factor
9%
Side Effect
9%
Reproductive Success
9%
Tamoxifen
9%
Health Care Cost
8%